Antibiotice S.A.

BVB:ATB Stock Report

Market Cap: RON 2.2b

Antibiotice Past Earnings Performance

Past criteria checks 4/6

Antibiotice has been growing earnings at an average annual rate of 29%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 13.2% per year. Antibiotice's return on equity is 10.8%, and it has net margins of 14.3%.

Key information

29.0%

Earnings growth rate

29.0%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate13.2%
Return on equity10.8%
Net Margin14.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Jun 07
Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

Jan 30
Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

Jan 13
We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Aug 16
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Is Antibiotice (BVB:ATB) A Risky Investment?

Jun 08
Is Antibiotice (BVB:ATB) A Risky Investment?

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Feb 11
Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Jan 12
Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 16
Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 24
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Revenue & Expenses Breakdown

How Antibiotice makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BVB:ATB Revenue, expenses and earnings (RON Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24651931640
31 Mar 24619961610
31 Dec 23615811620
30 Sep 23605991520
30 Jun 23572791390
31 Mar 23556651410
31 Dec 22505511310
30 Sep 22498411260
30 Jun 22467451360
31 Mar 22440351270
31 Dec 21379301260
30 Sep 21394271260
30 Jun 21366271240
31 Mar 21342261220
31 Dec 20347261180
30 Sep 20357271170
30 Jun 20370281120
31 Mar 20403321080
31 Dec 19395311080
30 Sep 19371351020
30 Jun 19385371020
31 Mar 19375341000
31 Dec 1836934970
30 Sep 1834834870
30 Jun 1835134890
31 Mar 1834432820
31 Dec 1733934790
30 Sep 1734433820
30 Jun 1734133680
31 Mar 1733829680
31 Dec 1633730670
30 Sep 1634330690
30 Jun 1634528720
31 Mar 1633628730
31 Dec 1533427720
30 Sep 1532125590
30 Jun 1530528740
31 Mar 1531432690
31 Dec 1432231690
30 Sep 1432034590
30 Jun 1432732550
31 Mar 1432132580
31 Dec 1332031590

Quality Earnings: ATB has high quality earnings.

Growing Profit Margin: ATB's current net profit margins (14.3%) are higher than last year (13.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ATB's earnings have grown significantly by 29% per year over the past 5 years.

Accelerating Growth: ATB's earnings growth over the past year (17.3%) is below its 5-year average (29% per year).

Earnings vs Industry: ATB earnings growth over the past year (17.3%) exceeded the Pharmaceuticals industry 10.2%.

Return on Equity

High ROE: ATB's Return on Equity (10.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y